Anivia Tablet 25 mg (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.
MFDS item code 202004032 · Approved 2020.05.29
This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps improve blood sugar control in patients with type 2 diabetes as an adjunct to dietary and exercise therapy. It can be used as monotherapy when treatment is initiated. If blood sugar control is difficult with monotherapy, it may be used in combination with metformin. Additionally, this medication can be added when blood sugar control is insufficient with other diabetes medications, such as sulfonylureas, thiazolidinediones, or insulin, either alone or in combination therapy. It aids effectively in managing blood sugar at various stages of treatment. Therefore, this medication is used to enhance blood sugar control in patients with type 2 diabetes.
This medicine is administered once daily at a dose of 100 mg when used as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2) should receive 50 mg once daily. 4. Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2) should receive 25 mg once daily. This medicine may be administered without regard to the timing of dialysis.
This medication may cause severe allergic reactions, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a healthcare provider. This medication may cause serious pancreatic inflammation known as pancreatitis; if symptoms such as abdominal pain, vomiting, or loss of appetite occur while taking it, inform a doctor immediately. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients with impaired renal function may need dosage adjustments, and regular renal function tests are important. Cold symptoms, headaches, and upper respiratory infections may occur during treatment, so consult with a healthcare provider if symptoms persist. There is an increased risk of hypoglycemia when used with other blood glucose-lowering medications or insulin; therefore, check blood sugar levels frequently and adjust dosage if necessary. If severe joint pain or skin blisters occur, discontinue this medication and consult a doctor. Pregnant or breastfeeding women are advised to avoid using this medication, and safety in children and adolescents under 18 has not been established. If an overdose occurs, seek proper treatment at a hospital immediately, and it can be partially removed by hemodialysis. This medication does not significantly increase the risk of major cardiovascular issues, but regular health check-ups are necessary during treatment.
Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, upper respiratory tract infections, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, constipation, vomiting, arthralgia with severe and disabling symptoms, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, ideally at room temperature between 1 and 30 degrees Celsius. This helps maintain the medication's effectiveness and prevents degradation.
Light orange, round, biconvex, film-coated tablet
28 tablets) 14 tablets/PPT (x2), 30 tablets) 10 tablets/PPT (x3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.